论文部分内容阅读
目的:利用包裹阿霉素的血管内皮生长因子(VEGF)-脂质体于体外观察其对肿瘤血管内皮细胞的杀伤作用。方法:利用体外细胞毒实验(MTT)方法,检测VEGF-阿霉素脂质体对肿瘤血管内皮细胞的杀伤作用。结果:48h细胞毒试验连有VEGF的阿霉素脂质体对肿瘤血管内皮细胞的杀伤作用优于无VEGF的阿霉素脂质体(P<0.05),而对非靶细胞(人血管平滑肌细胞)的杀伤作用两者相近。0.5 h预处理试验表明:缩短药物与细胞接触时间后,VEGF-阿霉素脂质体仍保持较强的杀伤肿瘤血管内皮细胞的作用。结论:VEGF修饰的阿霉素脂质体对肿瘤血管内皮细胞的杀伤作用较无VEGF组和非靶细胞组强,可望成为一种有效的抗肿瘤物质。
OBJECTIVE: To observe the cytotoxicity of doxorubicin on vascular endothelial cells in vitro by using vascular endothelial growth factor (VEGF) - liposomes. Methods: The cytotoxicity of VEGF-doxorubicin liposomes on tumor vascular endothelial cells was detected by MTT assay. Results: The 48h cytotoxicity assay showed that the doxorubicin liposomes with VEGF were more effective than the non-VEGF doxorubicin liposomes (P <0.05), but not with non-target cells (human vascular smooth muscle Cell) killing effect between the two similar. 0.5 h pretreatment experiments show that: shorten the drug and cell contact time, VEGF-doxorubicin liposomes still maintain a strong anti-tumor vascular endothelial cells. CONCLUSION: VEGF-modified doxorubicin liposomes can kill tumor vascular endothelial cells more effectively than non-VEGF and non-target cells, which is expected to be an effective anti-tumor substance.